EGFR and non-small cell lung carcinoma: This particular investigation analyzed therapeutic outcomes within a total of 120 clinical cases of advanced EGFR mutation-positive NSCLC across two separate cohorts control cohort (CC) - treated with conventional chemotherapy alone; observation cohort (OC) - treated with conventional chemotherapy + gefitinib [24].